BACKGROUND: The translocator protein (TSPO; 18 kDa), the new name of the peripheral-type benzodiazepine receptor, is localised in mitochondria of glial cells and expressed in very low concentrations in normal brain. Their expression rises after microglial activation following brain injury. Accordingly, TSPO are potential targets to evaluate neuroinflammatory changes in a variety of CNS disorders. PURPOSE: To date, only a few effective tools are available to explore TSPO by SPECT. We characterised here 6-chloro-2-(4'iodophenyl)-3-(N,N-diethyl)-imidazo[1,2-a]pyridine-3-acetamide or CLINDE in a rat model with different stages of excitotoxic lesion. METHODS: Excitotoxicity was induced in male Wistar rats by unilateral intrastriatal injection of different amounts of quinolinic acid (75, 150 or 300 nmol). Six days later, two groups of rats (n = 5-6/group) were i.v. injected with [(125)I]-CLINDE (0.4 MBq); one group being pre-injected with PK11195 (5 mg/kg). Brains were removed 30 min after tracer injection and the radioactivity of cerebral areas measured. Complementary ex vivo autoradiography, in vitro autoradiography ([(3)H]-PK11195) and immunohistochemical studies (OX-42) were performed on brain sections. RESULTS: In the control group, [(125)I]-CLINDE binding was significantly higher (p < 0.001) in lesioned than that in intact side. This binding disappeared in rats pre-treated with PK11195 (p < 0.001), showing specific binding of CLINDE to TSPO. Ex vivo and in vitro autoradiographic studies and immunohistochemistry were consistent with this, revealing a spatial correspondence between radioactivity signal and activated microglia. Regression analysis yielded a positive relation between the ligand binding and the degree of neuroinflammation. CONCLUSION: These results demonstrate that CLINDE is suitable for TSPO in vivo SPECT imaging to explore their involvement in neurodegenerative disorders associated with microglial activation.
BACKGROUND: The translocator protein (TSPO; 18 kDa), the new name of the peripheral-type benzodiazepine receptor, is localised in mitochondria of glial cells and expressed in very low concentrations in normal brain. Their expression rises after microglial activation following brain injury. Accordingly, TSPO are potential targets to evaluate neuroinflammatory changes in a variety of CNS disorders. PURPOSE: To date, only a few effective tools are available to explore TSPO by SPECT. We characterised here 6-chloro-2-(4'iodophenyl)-3-(N,N-diethyl)-imidazo[1,2-a]pyridine-3-acetamide or CLINDE in a rat model with different stages of excitotoxic lesion. METHODS: Excitotoxicity was induced in male Wistar rats by unilateral intrastriatal injection of different amounts of quinolinic acid (75, 150 or 300 nmol). Six days later, two groups of rats (n = 5-6/group) were i.v. injected with [(125)I]-CLINDE (0.4 MBq); one group being pre-injected with PK11195 (5 mg/kg). Brains were removed 30 min after tracer injection and the radioactivity of cerebral areas measured. Complementary ex vivo autoradiography, in vitro autoradiography ([(3)H]-PK11195) and immunohistochemical studies (OX-42) were performed on brain sections. RESULTS: In the control group, [(125)I]-CLINDE binding was significantly higher (p < 0.001) in lesioned than that in intact side. This binding disappeared in rats pre-treated with PK11195 (p < 0.001), showing specific binding of CLINDE to TSPO. Ex vivo and in vitro autoradiographic studies and immunohistochemistry were consistent with this, revealing a spatial correspondence between radioactivity signal and activated microglia. Regression analysis yielded a positive relation between the ligand binding and the degree of neuroinflammation. CONCLUSION: These results demonstrate that CLINDE is suitable for TSPO in vivo SPECT imaging to explore their involvement in neurodegenerative disorders associated with microglial activation.
Authors: Vassilios Papadopoulos; Mario Baraldi; Tomás R Guilarte; Thomas B Knudsen; Jean-Jacques Lacapère; Peter Lindemann; Michael D Norenberg; David Nutt; Abraham Weizman; Ming-Rong Zhang; Moshe Gavish Journal: Trends Pharmacol Sci Date: 2006-07-05 Impact factor: 14.819
Authors: Sriram Venneti; Brian J Lopresti; Guoji Wang; Susan L Slagel; N Scott Mason; Chester A Mathis; Michelle L Fischer; Niccole J Larsen; Amanda D Mortimer; Teresa G Hastings; Amanda D Smith; Michael J Zigmond; Tetsuya Suhara; Makoto Higuchi; Clayton A Wiley Journal: J Neurochem Date: 2007-06-07 Impact factor: 5.372
Authors: Lijun Li; Mannie Fan; Carolyn D Icton; Nansheng Chen; Blair R Leavitt; Michael R Hayden; Tim H Murphy; Lynn A Raymond Journal: Neurobiol Aging Date: 2003-12 Impact factor: 4.673
Authors: Filomena Mattner; David Linares Bandin; Maria Staykova; Paula Berghofer; Marie Claude Gregoire; Patrice Ballantyne; Mitchell Quinlivan; Susan Fordham; Tien Pham; David O Willenborg; Andrew Katsifis Journal: Eur J Nucl Med Mol Imaging Date: 2011-04-12 Impact factor: 9.236
Authors: P D Callaghan; C A Wimberley; G L Rahardjo; P J Berghofer; T Q Pham; T Jackson; D Zahra; T Bourdier; N Wyatt; I Greguric; N R Howell; R Siegele; Z Pastuovic; F Mattner; C Loc'h; M C Gregoire; A Katsifis Journal: Eur J Nucl Med Mol Imaging Date: 2014-09-18 Impact factor: 9.236
Authors: André F Martins; Jean-François Morfin; Anna Kubíčková; Vojtěch Kubíček; Frédéric Buron; Franck Suzenet; Milena Salerno; Adina N Lazar; Charles Duyckaerts; Nicolas Arlicot; Denis Guilloteau; Carlos F G C Geraldes; Eva Tóth Journal: ACS Med Chem Lett Date: 2013-04-15 Impact factor: 4.345
Authors: Cornelius K Donat; Khaled Gaber; Jürgen Meixensberger; Peter Brust; Lars H Pinborg; Henrik H Hansen; Jens D Mikkelsen Journal: Neuromolecular Med Date: 2016-03-11 Impact factor: 3.843
Authors: Benjamin B Tournier; Stergios Tsartsalis; Kelly Ceyzériat; Zadith Medina; Ben H Fraser; Marie-Claude Grégoire; Enikö Kövari; Philippe Millet Journal: J Cereb Blood Flow Metab Date: 2019-06-26 Impact factor: 6.200
Authors: Craig P Motbey; Emily Karanges; Kong M Li; Shane Wilkinson; Adam R Winstock; John Ramsay; Callum Hicks; Michael D Kendig; Naomi Wyatt; Paul D Callaghan; Iain S McGregor Journal: PLoS One Date: 2012-09-18 Impact factor: 3.240